Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01419158 · ClinicalTrials.gov registry record
Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)
A clinical trial, sponsored by Alpha-1 Foundation.
- Completed
- Registry status
- 3,457
- Enrollment target
NCT01419158: Completed study, sponsored by Alpha-1 Foundation.
NCT01419158 is a clinical trial that has completed, run by Alpha-1 Foundation. The registered enrollment target is 3,457 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01419158 has completed, sponsored by Alpha-1 Foundation.
- COMPLETED
- Registry status
- 3,457 participants
- Enrollment target
Study Summary
Alpha-1 antitrypsin deficiency (AATD) is considered a rare genetic cause of chronic obstructive pulmonary disease (COPD) and liver disease. Recent data has suggested that AATD is not as rare as originally thought and undetected AATD may account for COPD in some patients. This study was designed to evaluate the frequency of undetected AATD in a population reporting to academic pulmonary function testing facilities who meet criteria for the diagnosis of COPD. All individuals meeting GOLD criteria for COPD will be consented and offered free testing for AATD. The results will help identify the percent of those with COPD who have undetected AATD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,457 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-01 |
What the finished NCT01419158 record still lists
NCT01419158 is an observational study that tracks outcomes without assigning an intervention. Its 3,457 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01419158 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01419158 about?
NCT01419158 is a clinical study titled "Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)". Alpha-1 antitrypsin deficiency (AATD) is considered a rare genetic cause of chronic obstructive pulmonary disease (COPD) and liver disease. Recent data has suggested that AATD is not as rare as originally thought and undetected AATD may account for COPD in some patients. This study was designed to e...
What is the current status of trial NCT01419158?
This trial is currently completed. The enrollment target is 3,457 participants. The study started on 2008-01. Estimated completion is 2010-01.
Who is sponsoring clinical trial NCT01419158?
This trial is sponsored by Alpha-1 Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia